Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Ann Surg. 2021 Dec 1;274(6):1058–1066. doi: 10.1097/SLA.0000000000003770

TABLE 2.

Clinicopathologic Features of Patients Who Received Various Adjuvant Treatments After Resection of Pancreatic Cancer

Variable Total None RT Chemo RT-chemo Chemo-RT P Value
Median survival (m) 22.1 18.9 10.0 30.3 22.2 36.4 <0.001
Median Follow-up (m) 42.9 41.6 51.5 40.8 43.0 46.4 <0.001
Grade
  1 1677 (10.3%) 680 (12.13%) 18 (13.43%) 520 (8.75%) 35 (12.59%) 424 (9.87%) <0.001
  2 8359 (51.4%) 2793 (49.81%) 66 (49.25%) 3085 (51.88%) 131 (47.12%) 2284 (53.18%)
  3 5995 (36.9%) 2044 (36.45%) 48 (35.82%) 2254 (37.91%) 108 (38.85%) 1541 (35.88%)
  4 229 (1.4%) 90 (1.61%) 2 (1.49%) 87 (1.46%) 4 (1.44%) 46 (1.07%)
Stage
  1 2011 (12.0%) 1059 (18%) 14 (9.66%) 623 (10.56%) 16 (5.5%) 299 (6.66%) <0.001
  2 14145 (84.7%) 4634 (78.76%) 122 (84.14%) 5108 (86.56%) 263 (90.38%) 4018 (89.53%)
  3 553 (3.3%) 191 (3.25%) 9 (6.21%) 170 (2.88%) 12 (4.12%) 171 (3.81%)
Nodes
  Negative 5301 (32.6%) 2268 (40.11%) 48 (34.29%) 1777 (30.75%) 72 (25.71%) 1136 (25.73%) <0.001
  Positive 10,967 (67.4%) 3386 (59.89%) 92 (65.71%) 4002 (69.25%) 208 (74.29%) 3279 (74.27%)
Lymph node ratio 0.170.20 0.160.21 0.160.19 0.170.20 0.200.21 0.180.21 <0.001
LVI
  No 7117 (49.0%) 2750 (53.6%) 64 (56.14%) 2362 (45.91%) 123 (47.67%) 1818 (46.98%) <0.001
  Yes 7401 (51.0%) 2381 (46.4%) 50 (43.86%) 2783 (54.09%) 135 (52.33%) 2052 (53.02%)
Tumor size 35.5±32.7 35.8±34.6 35.3±15.8 35.0±29.2 37.0±22.8 35.7±35.5 0.59
T
  1 975 (6.0%) 495 (8.58%) 8 (5.63%) 327 (5.61%) 11 (3.86%) 134 (3.03%) <0.001
  2 2003 (12.3%) 825 (14.3%) 14 (9.86%) 674 (11.56%) 20 (7.02%) 470 (10.63%)
  3 12,918 (79.3%) 4223 (73.18%) 110 (77.46%) 4671 (80.12%) 248 (87.02%) 3666 (82.88%)
  4 385 (2.7%) 135 (2.34%) 7 (4.93%) 108 (1.85%) 6 (2.11%) 129 (2.92%)
Margin
  No 12,568 (76.6%) 4496 (77.83%) 88 (63.31%) 4707 (81.25%) 177 (62.11%) 3100 (70.15%) <0.001
  Yes 3845 (23.4%) 1281 (22.17%) 51 (36.69%) 1086 (18.75%) 108 (37.89%) 1319 (29.85%)

All the treatments are in the adjuvant setting.

Chemo indicates chemotherapy; Chemo-RT, chemotherapy followed by radiation; LVI, lymphovascular invasion; XRT, radiation; RT-Chemo, radiation followed by chemotherapy